Arylepoxamides

Arylepoxamides are a new class of analgesics that have potent efficacy with limited side effects.

Pipeline

Precision Neuropsychiatry

Use of fMRI and advanced analytics to develop and discover drugs for neuropsychiatric diseases. 

Mitragynine Derivative

Derived from the Kratom plant, this class of drug has potential for the treatment of opioid use disorders. 

 

Arylepoxamides

Pain relief without the side effects

Arylepoxamides are novel compounds which binds to a newly discovered receptor, AEAr. The AEAr is widely distributed thoughout the neuro-axis. In preclinical studies, arylepoxamides demonstrate potent analgesia and a clean safety profile lacking respiratory depression, physical dependence and reward behavior.

SBS-1000 - i.v. / s.c. formulation 

Preclinical IND-enabling tox ongoing

Phase 1 clinical anticipated in 2021

SBS-1226 - oral formulation 

Discovery / preclinical development

SBS-972 - i.v. / s.c. formulation

Discovery / preclinical development

 

Mitragynine Derivatives

Attacking addiction and overdose head on

Mitragynine derives from the kratom plant. The Pasternak lab has characterized its unique pharmacologic profile. It has attributes which make it a suitable candidate for opioid use disorder.

SBS-1027
Discovery / Preclinical Development 

 

Precision Neuropsychiatry

Bringing personalized medicine to the brain 

Sparian is collaborating with a spin out of the Brigham and Women's Hospital/Harvard Medical School which is pioneering the use of functional MRI (fMRI) technology and advanced analytics to better understand the neurobiology of disease and the response to treatment. We are looking to use this technology to enhance the precision and success of neuropsychiatric drug development.  

© 2020 Sparian Biosciences Inc